Drug intelligence / Profile preview

pf8001

Development stage: Preclinical
Lead developer: Ensysce Biosciences
Modality: Small Molecules
Administration: Oral

Overview

PF8001 is a small molecule drug being developed as an abuse-resistant amphetamine formulation for the treatment of attention-deficit hyperactivity disorder (ADHD). It is being developed in both extended release and immediate release formulations (paired with PF8026). The drug is part of Ensysce Biosciences' portfolio of abuse-deterrent medications.

Targets

SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on pf8001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pf8001.

Explore the full profile